HeartMate 3与HeartWare左心室辅助装置单中心200例1年结局回顾性随访
该单中心回顾性研究纳入200例植入HeartMate 3(HM3)或HeartWare HVAD(HW)左心室辅助装置的患者,各100例,比较术前资料、并发症及1年结局。结果显示两组1年生存率相似,但HW组脑出血和血液相容性相关不良事件发生率显著更高。
要点
- HM3与HW两组1年生存率相似,早期生存可比。
- HW组脑出血发生率显著高于HM3组(HR 6.79)。
- HW组血液相容性相关不良事件显著更多(P<0.001)。
核心结论
- 两种泵的并发症谱不同,但早期生存率相当。
研究设计与样本
- 单中心回顾性分析,纳入2015年10月至2017年4月间100例HW和100例HM3左心室辅助装置植入患者,随访1年。
主要发现
- HW组73%为INTERMACS I或II级,HM3组为57%(P=0.018)。
- HW组脑出血发生率更高[HR 6.79(1.43-32.20),P=0.016]。
- HW组血液相容性相关不良事件显著更高(1.28 vs 0.7事件/患者年,P<0.001)。
- 两组1年生存率相似[62.2%,95%CI(0.53-0.73)vs 66.7%,95%CI(0.58-0.767)]。
关键数值与推荐
- 抗凝方案相似,目标INR 2.5-3.0,家庭监测,平均动脉压目标70-80 mmHg。
临床怎么用
- 选择左心室辅助装置时需权衡并发症谱,HW与更高的脑出血和血液相容性事件相关。
局限性
- 单中心回顾性设计,样本量有限,随访仅1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Various trials have assessed the outcome and reliability of the HeartWare HVAD (HW) and HeartMate 3 (HM3) left ventricular assist devices. A direct comparison of clinical outcomes and of the complication profile of these 2 left ventricular assist devices is lacking. We present a retrospective analysis of patients supported with HM3 and HW as a left ventricular assist device. METHODS: Preoperative data, complications and outcomes including a 1-year follow-up of patients supported with the HM3 and HW in a single centre were retrospectively analysed. Both pumps were implanted on- or off-pump, employing standard and minimally invasive techniques. For logistic reasons, the 2 device types were implanted in an alternating manner, thereby reducing the systematic bias for pump selection. We considered this to be an appropriate approach, as no differences in respect of survival or the complication profile of the two device types have been demonstrated. Anticoagulation was similar in patients with both pumps according to our anticoagulation protocol, with a target international normalized ratio of 2.5-3.0, a home monitoring system and blood pressure management with a mean arterial target pressure of 70-80 mmHg. RESULTS: Between October 2015 and April 2017, 100 patients underwent implantation of the HW and 100 patients underwent implantation of the HM3. The median time on the device was 0.98 years (range 0-2.23 years). The median age was 58.5 (51-65) versus 57 (49-64) years (P = 0.456); the number of male patients was 87 versus 88 (P = 0.831). Of the HW patients, 73% were rated as having an INTERMACS level I or II, compared to 57% of the HM3 patients (P = 0.018). There were no further differences in preoperative data. A total of 14 patients had pre-, intra- or post-pump blood flow obstruction in the HW group versus 4 in the HM3 group [hazard ratio (HR) 2.5 (0.7-8.8), P = 0.103]. There were no differences regarding gastrointestinal bleeding [HR 1.25 (0.56-2.64), P = 0.624] or driveline infection (0.68 vs 0.8 events per patient-year, P = 0.0789). The incidence of ischaemic stroke was similar in both groups [HR 0.72 (0.25-2.09), P = 0.550]. Cerebral bleeding was more frequent in patients supported with HW [HR 6.79 (1.43-32.20), P = 0.016]. The incidence of cerebrovascular accidents, on the other hand, was similar in both groups [HR 1.85 (0.83-4.19), P = 0.13]. The incidence of haemocompatibility-related adverse events, however, was significantly higher in the HW group (113 points corresponding to 1.28 events per patient-year versus 69 points corresponding to 0.7 events per patient-year, P < 0.001). The 1-year survival was similar in both groups [62.2%, 95% confidence interval (CI) (0.53-0.73) vs 66.7%, 95% CI (0.58–0.767) [corrected]. CONCLUSIONS: Our data show that the complication profile differs between the 2 pumps, but that early survival is comparable.
引用
- Mueller M, Hoermandinger C, Richter G, et al. Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre. Eur J Cardiothorac Surg. 2020. PMID: 32298426. doi:10.1093/ejcts/ezaa017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。